目的 探讨ω-3多不饱和脂肪酸(ω-3 PUFA)对大鼠创伤性脑损伤(TBI)后脑水肿、自噬反应及神经功能的影响及其机制.方法 采用改良Feeney法建立大鼠TBI模型,将72只SD大鼠采用随机数字表法分为假手术组、TBI组、TBI+ ω-3 PUFA处理组(TBI+ ω-3组)和TBI+自噬抑制剂3-甲基腺嘌呤组(TBI+3-MA组)(n均=18),各组再根据3个时间点(创伤后第1、3、7天)分设3个亚组(n=6).于不同时间点采用改良神经功能评分表(mNSS)进行神经功能评分,采用干湿重法测量损伤区脑组织水含量,于建模后第3天采用免疫荧光、PCR和Westerrnblot法测定自噬相关因子(LC3-Ⅱ、Beclin-1)的mRNA及蛋白表达水平.结果 损伤后第1、3、7天,与假手术组比较,TBI组、TBI+ ω-3组和TBI+ 3-MA组的mNSS评分(TBI组:12.42 ±0.27比1.34±0.32,12.07±0.27比1.16±0.29,10.22±0.39比1.22±0.30;TBI+ ω-3组:12.05±0.23比1.34±0.32,11.38±0.21比1.16±0.29,8.20±0.21比1.22±0.30;TBI+ 3-MA组:11.93±0.20比1.34±0.32,11.09±0.19比1.16±0.29,7.93±0.17比1.22±0.30;P均=0.00)和脑水含量均显著升高[TBI组:(79.82±0.61)%比(71.87±0.43)%,(83.04±0.42)%比(72.13±0.53)%,(75.12±0.72)%比(71.78±0.38)%;TBI +ω-3组:(76.81±0.63)%比(71.87±0.43)%,(79.39±0.59)%比(72.13±0.53)%,(73.86±0.38)%比(71.78±0.38)%;TBI+ 3-MA组:(75.98±0.49)%比(71.87±0.43)%,(77.14±0.46)%比(72.13±0.53)%,(72.24±0.37)%比(71.78±0.38)%;P均=0.00].模型建立后第3天,TBI组、TBI+ ω-3组和TBI+ 3-MA组脑组织LC3-Ⅱ和Beclin-1的mRNA及蛋白表达均显著上调(P均=0.00).模型建立后第3、7天,TBI+ ω-3组和TBI+ 3-MA组的mNSS评分均显著低于TBI组(TBI+ ω-3组:11.38±0.21比12.07±0.27、P=0.04,8.20±0.21比10.22±0.39、P=0.01;TBI+ 3-MA组:11.09±0.19比12.07±0.27、P=0.01,7.93±0.17比10.22±0.39、P=0.00);模型建立后第1、3、7天脑组织含水量均显著低于TBI组[TBI+ ω-3组:(76.81±0.63)%比(79.82±0.61)%、P=0.04,(79.39±0.59)%比(83.04±0.42)%、P=0.01,(73.86±0.38)%比(75.12±0.72)%、P=0.03;TBI+ 3-MA组:(75.98±0.49)%比(79.82±0.61)%、P=0.01,(77.14±0.46)%比(83.04±0.42)%、P=0.00,(72.24±0.37)%比(75.12±0.72)%、P=0.02];第3天脑组织LC3-Ⅱ和Beclin-1的mRNA(TBI+ ω-3组:P=0.04,P=0.01;TBI+ 3-MA组:P=0.01,P=0.00)及蛋白表达(TBI+ω-3组:P=0.01,P=0.03;TBI+3-MA组:P均=0.00)均显著低于TBI组.结论 ω-3 PUFA可减轻大鼠TBI后脑水肿,改善创伤后神经功能,具有神经保护作用,其机制可能与降低颅脑损伤后神经细胞自噬反应相关.
目的 探討ω-3多不飽和脂肪痠(ω-3 PUFA)對大鼠創傷性腦損傷(TBI)後腦水腫、自噬反應及神經功能的影響及其機製.方法 採用改良Feeney法建立大鼠TBI模型,將72隻SD大鼠採用隨機數字錶法分為假手術組、TBI組、TBI+ ω-3 PUFA處理組(TBI+ ω-3組)和TBI+自噬抑製劑3-甲基腺嘌呤組(TBI+3-MA組)(n均=18),各組再根據3箇時間點(創傷後第1、3、7天)分設3箇亞組(n=6).于不同時間點採用改良神經功能評分錶(mNSS)進行神經功能評分,採用榦濕重法測量損傷區腦組織水含量,于建模後第3天採用免疫熒光、PCR和Westerrnblot法測定自噬相關因子(LC3-Ⅱ、Beclin-1)的mRNA及蛋白錶達水平.結果 損傷後第1、3、7天,與假手術組比較,TBI組、TBI+ ω-3組和TBI+ 3-MA組的mNSS評分(TBI組:12.42 ±0.27比1.34±0.32,12.07±0.27比1.16±0.29,10.22±0.39比1.22±0.30;TBI+ ω-3組:12.05±0.23比1.34±0.32,11.38±0.21比1.16±0.29,8.20±0.21比1.22±0.30;TBI+ 3-MA組:11.93±0.20比1.34±0.32,11.09±0.19比1.16±0.29,7.93±0.17比1.22±0.30;P均=0.00)和腦水含量均顯著升高[TBI組:(79.82±0.61)%比(71.87±0.43)%,(83.04±0.42)%比(72.13±0.53)%,(75.12±0.72)%比(71.78±0.38)%;TBI +ω-3組:(76.81±0.63)%比(71.87±0.43)%,(79.39±0.59)%比(72.13±0.53)%,(73.86±0.38)%比(71.78±0.38)%;TBI+ 3-MA組:(75.98±0.49)%比(71.87±0.43)%,(77.14±0.46)%比(72.13±0.53)%,(72.24±0.37)%比(71.78±0.38)%;P均=0.00].模型建立後第3天,TBI組、TBI+ ω-3組和TBI+ 3-MA組腦組織LC3-Ⅱ和Beclin-1的mRNA及蛋白錶達均顯著上調(P均=0.00).模型建立後第3、7天,TBI+ ω-3組和TBI+ 3-MA組的mNSS評分均顯著低于TBI組(TBI+ ω-3組:11.38±0.21比12.07±0.27、P=0.04,8.20±0.21比10.22±0.39、P=0.01;TBI+ 3-MA組:11.09±0.19比12.07±0.27、P=0.01,7.93±0.17比10.22±0.39、P=0.00);模型建立後第1、3、7天腦組織含水量均顯著低于TBI組[TBI+ ω-3組:(76.81±0.63)%比(79.82±0.61)%、P=0.04,(79.39±0.59)%比(83.04±0.42)%、P=0.01,(73.86±0.38)%比(75.12±0.72)%、P=0.03;TBI+ 3-MA組:(75.98±0.49)%比(79.82±0.61)%、P=0.01,(77.14±0.46)%比(83.04±0.42)%、P=0.00,(72.24±0.37)%比(75.12±0.72)%、P=0.02];第3天腦組織LC3-Ⅱ和Beclin-1的mRNA(TBI+ ω-3組:P=0.04,P=0.01;TBI+ 3-MA組:P=0.01,P=0.00)及蛋白錶達(TBI+ω-3組:P=0.01,P=0.03;TBI+3-MA組:P均=0.00)均顯著低于TBI組.結論 ω-3 PUFA可減輕大鼠TBI後腦水腫,改善創傷後神經功能,具有神經保護作用,其機製可能與降低顱腦損傷後神經細胞自噬反應相關.
목적 탐토ω-3다불포화지방산(ω-3 PUFA)대대서창상성뇌손상(TBI)후뇌수종、자서반응급신경공능적영향급기궤제.방법 채용개량Feeney법건립대서TBI모형,장72지SD대서채용수궤수자표법분위가수술조、TBI조、TBI+ ω-3 PUFA처리조(TBI+ ω-3조)화TBI+자서억제제3-갑기선표령조(TBI+3-MA조)(n균=18),각조재근거3개시간점(창상후제1、3、7천)분설3개아조(n=6).우불동시간점채용개량신경공능평분표(mNSS)진행신경공능평분,채용간습중법측량손상구뇌조직수함량,우건모후제3천채용면역형광、PCR화Westerrnblot법측정자서상관인자(LC3-Ⅱ、Beclin-1)적mRNA급단백표체수평.결과 손상후제1、3、7천,여가수술조비교,TBI조、TBI+ ω-3조화TBI+ 3-MA조적mNSS평분(TBI조:12.42 ±0.27비1.34±0.32,12.07±0.27비1.16±0.29,10.22±0.39비1.22±0.30;TBI+ ω-3조:12.05±0.23비1.34±0.32,11.38±0.21비1.16±0.29,8.20±0.21비1.22±0.30;TBI+ 3-MA조:11.93±0.20비1.34±0.32,11.09±0.19비1.16±0.29,7.93±0.17비1.22±0.30;P균=0.00)화뇌수함량균현저승고[TBI조:(79.82±0.61)%비(71.87±0.43)%,(83.04±0.42)%비(72.13±0.53)%,(75.12±0.72)%비(71.78±0.38)%;TBI +ω-3조:(76.81±0.63)%비(71.87±0.43)%,(79.39±0.59)%비(72.13±0.53)%,(73.86±0.38)%비(71.78±0.38)%;TBI+ 3-MA조:(75.98±0.49)%비(71.87±0.43)%,(77.14±0.46)%비(72.13±0.53)%,(72.24±0.37)%비(71.78±0.38)%;P균=0.00].모형건립후제3천,TBI조、TBI+ ω-3조화TBI+ 3-MA조뇌조직LC3-Ⅱ화Beclin-1적mRNA급단백표체균현저상조(P균=0.00).모형건립후제3、7천,TBI+ ω-3조화TBI+ 3-MA조적mNSS평분균현저저우TBI조(TBI+ ω-3조:11.38±0.21비12.07±0.27、P=0.04,8.20±0.21비10.22±0.39、P=0.01;TBI+ 3-MA조:11.09±0.19비12.07±0.27、P=0.01,7.93±0.17비10.22±0.39、P=0.00);모형건립후제1、3、7천뇌조직함수량균현저저우TBI조[TBI+ ω-3조:(76.81±0.63)%비(79.82±0.61)%、P=0.04,(79.39±0.59)%비(83.04±0.42)%、P=0.01,(73.86±0.38)%비(75.12±0.72)%、P=0.03;TBI+ 3-MA조:(75.98±0.49)%비(79.82±0.61)%、P=0.01,(77.14±0.46)%비(83.04±0.42)%、P=0.00,(72.24±0.37)%비(75.12±0.72)%、P=0.02];제3천뇌조직LC3-Ⅱ화Beclin-1적mRNA(TBI+ ω-3조:P=0.04,P=0.01;TBI+ 3-MA조:P=0.01,P=0.00)급단백표체(TBI+ω-3조:P=0.01,P=0.03;TBI+3-MA조:P균=0.00)균현저저우TBI조.결론 ω-3 PUFA가감경대서TBI후뇌수종,개선창상후신경공능,구유신경보호작용,기궤제가능여강저로뇌손상후신경세포자서반응상관.
Objective To investigate the effects of omega-3 polyunsaturated fatty acids (ω-3 PUFA)supplementation on brain edema,autophagy response and neurobehavioral outcome after traumatic brain injury (TBI) in rats and the related mechanisms.Methods TBI rat models were established using Feeney's method.Seventy-two SD rats were divided into 4 groups using random number table:sham operation group,TBI group,ω-3 PUFA supplementation group (TBI + ω-3 group) and autophagy inhibitor 3-methyladenine group (TBI + 3-MA group) (all n =18),each group was further divided into 3 sub-groups (n =6) corresponding to 3 time points (days 1,3,and 7 after TBI).On each of the 3 time points,we measured rat behavioral outcomes with modified neurologic severity score (mNSS) tests;brain water content was measured with wet-dry weight method.The mRNA and protein expressions of autophagy-related factors (LC3-Ⅱ and Beclin-1) in TBI cerebral cortex were determined by immunohistochemistry staining,reverse transcription-polymerase chain reaction and Western blot on day 3 after TBI.Results Compared with the sham group,on days 1,3,and 7 after injuary,the TBI group,the TBI + ω-3 group,and the TBI + 3-MA group had significantly higher mNSS scores (TBI group:12.42±0.27vs.1.34±0.32,12.07±0.27vs.1.16±0.29,10.22±0.39vs.1.22±0.30;TBI+ω-3 group:12.05 ±0.23 vs.1.34 ±0.32,11.38 ±0.21 vs.1.16±0.29,8.20 ±0.21 vs.1.22±0.30;TBI +3-MA group:11.93 ±0.20 vs.1.34 ±0.32,11.09 ±0.19 vs.1.16 ±0.29,7.93 ±0.17 vs.1.22 ± 0.30;all P =0.00) and brain water content [TBI group:(79.82 ± 0.61) % vs.(71.87 ± 0.43) %,(83.04±0.42)% vs.(72.13 ±0.53)%,(75.12 ±0.72)% vs.(71.78 ±0.38)%;TBI+ω-3 group:(76.81 ±0.63)% vs.(71.87 ±0.43)%,(79.39 ±0.59)% vs.(72.13 ±0.53)%,(73.86 ±0.38)% vs.(71.78 ±0.38)%;TBI+3-MAgroup:(75.98 ±0.49)% vs.(71.87 ±0.43)%,(77.14 ±0.46)% vs.(72.13 ±0.53)%,(72.24 ±0.37)% vs.(71.78 ±0.38)%;all P =0.00].The mRNA and protein expressions of LC3-Ⅱ and Beclin-1 in the brain were also significantly higher on day 3 in the TBI group,the TBI + ω-3 group,and the TBI + 3-MA group (all P =0.00).Compared with the TB1 group,on day 3 and day 7 after injury,the TBI + ω-3 group and the TBI + 3-MA group had significantly lower mNSS scores (TBI + ω-3 group:11.38±0.21 vs.12.07±0.27,P=0.04,8.20±0.21 vs.10.22±0.39,P=0.01;TBI+3-MA group:11.09±0.19vs.12.07 ± 0.27,P=0.01,7.93 ± 0.17 vs.10.22±0.39,P=0.00).Ondays1,3,and 7,compared with the TBI group,the TBI + ω-3 group and the TBI + 3-MA group had significantly lower brain water content [TBI + ω-3 group:(76.81 ± 0.63) % vs.(79.82 ± 0.61) %,P =0.04,(79.39 ±0.59)% vs.(83.04±0.42)%,P=0.01,(73.86±0.38)% vs.(75.12±0.72)%,P=0.03;TBI+3-MAgroup:(75.98 ±0.49)% vs.(79.82 ±0.61)%,P=0.01,(77.14 ±0.46)% vs.(83.04 ±0.42)%,P =0.00,(72.24 ± 0.37) % vs.(75.12 ± 0.72) %,P =0.02].On day 3,the TBI + ω-3 group and the TBI + 3-MA group had significantly reduced LC3-Ⅱ and Beclin-1 mRNA expression compared with the TBI group (TBI +ω-3 group:P=0.04,P =0.01;TBI +3-MA group:P =0.01,P =0.00) and protein expression (TBI+ω-3 group:P=0.01,P=0.03;TBI +3-MA group:both P=0.00).Conclusion ω-3 PUFA supplementation could markedly reduce brain edema and improve neurological functions after TBI,showing a neuroprotective effect,possibly through inhibiting TBI-induced autophagy responses.